ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.10024G>A (p.Glu3342Lys) (rs28897761)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000220854 SCV000274258 uncertain significance Hereditary cancer-predisposing syndrome 2019-03-22 criteria provided, single submitter clinical testing The p.E3342K variant (also known as c.10024G>A), located in coding exon 26 of the BRCA2 gene, results from a G to A substitution at nucleotide position 10024. The glutamic acid at codon 3342 is replaced by lysine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
GeneDx RCV000445222 SCV000526510 likely benign not specified 2016-12-13 criteria provided, single submitter clinical testing This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Invitae RCV000463710 SCV000549705 likely benign Hereditary breast and ovarian cancer syndrome 2020-12-04 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000445222 SCV000694487 uncertain significance not specified 2019-07-01 criteria provided, single submitter clinical testing Variant summary: BRCA2 c.10024G>A (p.Glu3342Lys) results in a conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 8e-06 in 250966 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. The variant, c.10024G>A, has been reported in the literature in individuals affected with breast and/or ovarian cancer (Alsop_2012, Azzollini_2016). However, these reports do not provide unequivocal conclusions about association of the variant with Hereditary Breast and Ovarian Cancer. One publication reports that this variant was found to co-occur with a pathogenic change but do specify the pathogenic variant (Alsop_2012). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Four other submitters have provided clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation (2x uncertain significance and 2x benign). Based on the evidence outlined above, the variant was classified as uncertain significance until additional information becomes available.
Color Health, Inc RCV000220854 SCV000911853 likely benign Hereditary cancer-predisposing syndrome 2018-01-03 criteria provided, single submitter clinical testing
Sharing Clinical Reports Project (SCRP) RCV000031299 SCV000053904 likely benign Breast-ovarian cancer, familial 2 2009-04-15 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.